Daily Clinical Briefing · Educational reading for healthcare professionals
Inotrope choice starts with perfusion, heart rate and afterload, not blood pressure alone.
Normal blood pressure does not exclude low cardiac output when cold skin, prolonged capillary refill or oliguria show hypoperfusion.
A normal blood pressure can coexist with important cardiac hypoperfusion. Cold skin, prolonged capillary refill and oliguria may be telling a different story, particularly when biomarkers and point-of-care ultrasound also suggest low cardiac output.
That apparent contradiction makes sense once blood pressure is separated from flow. Cardiac output depends on heart rate and stroke volume, while mean arterial pressure reflects both cardiac output and systemic vascular resistance. An inodilator can therefore increase cardiac output while lowering vascular resistance and leave mean arterial pressure almost unchanged.
The practical question is not simply which drug raises the pressure most.
Dobutamine increases contractility, with some tachycardia and vasodilation. Epinephrine adds stronger chronotropic and vasoconstrictive effects, but it can also increase lactate production and complicate interpretation of a rising lactate during treatment.
Milrinone works downstream of beta-adrenergic receptors and reduces both systemic and pulmonary vascular resistance. It usually produces less tachycardia than beta-agonists and may be useful when beta-blockade or right ventricular failure matters. Its vasodilation can worsen hypotension, however, and renal clearance becomes important when kidney function is impaired.
That makes the pre-inotrope assessment as important as the prescription. Review heart rate, ventricular dysfunction, beta-blocker exposure, renal function and systemic or pulmonary afterload. Record peripheral perfusion, capillary refill, urine output, relevant biomarkers and ultrasound findings, then repeat them after changing support.
Other measurements need the same discipline. Central and mixed venous oxygen saturations come from different sampling sites and should not be treated as interchangeable or diagnostic in isolation. Ionised calcium is also worth considering because it represents the calcium available for cellular function, particularly in settings such as massive transfusion, renal replacement therapy, high-dose loop diuretics or significant alkalosis.
BRASH syndrome shows why treating individual numbers can fail. AV nodal blockade and hyperkalaemia worsen bradycardia; falling cardiac output worsens renal perfusion and drug accumulation, reinforcing the cycle.
The useful endpoint is therefore not a particular blood-pressure number. It is whether the circulation is delivering better perfusion after the intervention. An unchanged mean arterial pressure may coexist with increased cardiac output, while a normal pressure in a cold, oliguric patient should not provide false reassurance.
South Asian cardiometabolic risk can be underestimated by BMI or broad dietary labels. Country of origin, ectopic fat, food quality, pregnancy, menopause and family history all refine assessment, while emerging calcium-imaging findings still require cautious interpretation.
Intravascular lithotripsy improves vessel preparation in calcified femoropopliteal disease compared with plain balloon angioplasty, with fewer flow-limiting dissections and provisional stents. Balloon sizing, lesion length and endpoint definitions are important when interpreting the reported procedural and patency results.
Torsades de pointes may present as recurrent brief blackouts with rapid recovery between episodes. Recognition of QT prolongation, withdrawal of contributing medicines, magnesium, correction of electrolytes and management of bradycardia or ventricular fibrillation are central to treatment.
Inotrope choice should follow the physiology: assess perfusion, heart rate, ventricular function, vascular resistance, beta-blocker exposure and renal function rather than blood pressure alone. Dobutamine, epinephrine and milrinone produce importantly different cardiac and vascular effects.
Citrin deficiency can produce neonatal acute liver failure without cholestasis and mimic citrullinaemia type 1 on newborn screening. Worsening synthetic function during high-carbohydrate treatment should prompt diagnostic review and rapid nutritional redirection.
Fregoli syndrome is the recurrent belief that different people are one familiar person in disguise. Later-life onset should raise concern for neurodegenerative disease, while dopaminergic medication is another potential contributor requiring review.
Vertigo assessment should use onset, duration, symptom-free intervals, hearing changes and vascular clues to separate peripheral from central causes, while recognising that a normal CT cannot exclude a small cerebellar stroke when clinical concern persists.
Practical neurology decisions include assessing infectious and autoimmune encephalitis in parallel, separating multiple sclerosis diagnosis from treatment, scrutinising misleading seizure measurements, supporting activity in uncomplicated back pain and interpreting early CAR T-cell evidence cautiously.
AI can support repeated spoken histories and examination rehearsal, but convincing simulation does not equal complete assessment; de-skilling, never-skilling and mis-skilling remain risks, and communication skills and physical examination still require practice with patients or colleagues.
Ethical stimulant prescribing requires balanced substance-related risk assessment, clinical independence and truthful documentation. Brief psychiatric consultations may reduce waiting times for selected simple referrals, but shorter waits alone do not demonstrate better care quality.
Haemodynamic tolerance determines immediate management of sustained wide-complex tachycardia, while recurrent sustained ventricular arrhythmias define electrical storm and prompt consideration of sedation, reversible causes and secondary-prevention defibrillator therapy.
Smoking treatment access, anticoagulation, coronary calcium scoring, colorectal screening and lipid lowering illustrate recurring evidence traps: treatment uptake is not persistence, relative effects can obscure small absolute benefits, and reassuring biomarkers or test results do not automatically establish clinical benefit.
Alcohol use disorder medication should match recovery goals, drinking pattern and comorbidity, with naltrexone, acamprosate, topiramate and other options assessed by meaningful changes in craving and control alongside continuing psychological and addiction support.
Before changing an inotrope, record peripheral perfusion, capillary refill, urine output, relevant biomarkers and ultrasound findings, then reassess them afterwards. Review heart rate, beta-blocker exposure, renal function and systemic or pulmonary afterload when choosing between agents. Do not use blood pressure alone as evidence of adequate perfusion.
A patient with acute decompensated heart failure receives an inodilator. Cardiac output rises and systemic vascular resistance falls, while mean arterial pressure changes very little. Does the almost unchanged pressure mean that cardiac output has failed to improve?
No. Increased cardiac output and reduced systemic vascular resistance can offset one another, leaving mean arterial pressure almost unchanged despite improved cardiac output.
A patient with right ventricular dysfunction and raised pulmonary pressures develops troublesome tachycardia on dobutamine. Blood pressure and renal function remain satisfactory. Which inotrope described offers contractile support, lowers pulmonary vascular resistance and usually causes less tachycardia?
Milrinone. It works downstream of beta-adrenergic receptors and lowers systemic and pulmonary vascular resistance, although hypotension, arrhythmias and renal clearance still need consideration.
A patient has recurrent brief episodes of loss of consciousness with rapid recovery, and monitoring identifies torsades de pointes with a prolonged QT interval. What medication and electrolyte issues should be addressed?
Review and withhold contributing QT-prolonging medicines and correct electrolyte abnormalities. Magnesium is used initially for torsades, with further treatment guided by recurrence and the accompanying heart rate and rhythm.
Daily Clinical Briefings are prepared using ChatGPT Pro from the show notes and educational output for that day’s episodes. Iain Beardsell then checks the briefing for accuracy.
This describes the current briefing process. Item-specific review dates are shown only where documented. The original podcasts remain the sources; MedPod’s briefing is additional educational material.
Read about MedPod’s editorial approach
Report an error or source concern — please include the article title and link, without patient-identifying information.
.svg)